样式: 排序: IF: - GO 导出 标记为已读
-
Recent developments in CD19-targeted therapies for follicular lymphoma. Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-09-18 Aditi Saha,Julio C Chavez
INTRODUCTION CD19 has emerged as an important and novel therapeutic target in follicular lymphoma. CD19-directed therapies, including monoclonal antibodies, bispecific antibodies, and CAR T-cell therapies, offer promising avenues for treating follicular lymphoma and improving outcomes. AREAS COVERED We review the role and rationale of targeting CD19 in follicular lymphoma and different interventions
-
The future of interleukin gene therapy in head and neck cancers. Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-09-18 Cosima C Hoch,Khouloud Hachani,Yu Han,Benedikt Schmidl,Markus Wirth,Gabriele Multhoff,Ali Bashiri Dezfouli,Barbara Wollenberg
INTRODUCTION Head and neck cancer (HNC), primarily head and neck squamous cell carcinomas, originates from the squamous epithelium in areas like the oral cavity, lip, larynx, and oropharynx. With high morbidity impacting critical functions, combined treatments like surgery, radiation, and chemotherapy often fall short in advanced stages, highlighting the need for innovative therapies. AREAS COVERED
-
Long-term progression-free survival in non-small cell lung cancer patients: a spotlight on bevacizumab and its biosimilars Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-09-16 Fran Seiwerth, Lela Bitar, Miroslav Samaržija, Marko Jakopović
In the era of immunotherapy, bevacizumab seems to be losing its place in NSCLC treatment algorithms. The aim of this work is to try to define the advantages and disadvantages of NSCLC treatment wit...
-
Mosunetuzumab for the treatment of follicular lymphoma Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-09-16 Caterina Labanca, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Francesco Mendicino, Paola De Luca, Eugenio Lucia, Virginia Olivito, Valentina Fragliasso, Antonino Neri, Fortunato Morabito, Massimo Gentile
Follicular lymphoma (FL) is an indolent non-Hodgkin lymphoma that shows a progressive increase in relapses and refractory in its natural history and a median survival of approximately 18–20 years. ...
-
Clinical experience of using biosimilars in Crohn’s disease and their effectiveness Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-09-13 Léa Sequier, Bénédicte Caron, Silvio Danese, Laurent Peyrin-Biroulet
The approval of biosimilars in the management of inflammatory bowel diseases (IBDs) has offered an answer to a growing concern about healthcare costs, and availability of treatments. Several studie...
-
Considerations for the use of biological therapies in elderly patients with rheumatoid arthritis Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-09-13 Noor Nooh, May N Lwin, Christopher Edwards
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that primarily affects middle-aged individuals but is increasingly prevalent among the elderly due to longer life expectancies...
-
The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-09-08 Qin-Yi Su, Heng-Yan Gao, Yue-Ru Duan, Jing Luo, Wei-Ze Wang, Xi-Chao Qiao, Sheng-Xiao Zhang
Psoriatic arthritis (PsA) is a debilitating chronic condition characterized by inflammation of the joints, bones, enthesis, and skin. The pivotal role of interleukin-23 (IL-23) in the pathogenesis ...
-
Physicians’ and patients’ perception of biosimilars and factors affecting biosimilar prescribing in selected Asian Countries: a survey study Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-09-05 Supat Thongpooswan, Anupam Das, Pravin Patil, Mark Latymer, Lyndon Llamado, James Wee
This study evaluated physicians’ and patients’ beliefs about biosimilars in Hong Kong, India, Pakistan, Singapore, Taiwan, and Thailand.An onlne survey administered to physicians (dermatologists, n...
-
An evaluation of exagamglogene autotemcel for the treatment of sickle cell disease and transfusion-dependent beta-thalassaemia Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-09-02 Rupert Handgretinger, Markus Mezger
Sickle cell disease is the most common hereditary hemoglobinopathy followed by beta-thalassemia. Until recently, allogeneic stem cell transplantation was the only curative approach. Based on the Cr...
-
The future of aptamers in cancer diagnosis, prognosis and treatment Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-08-30 Jazmine Arévalo, Adrian Gabriel Torres
Published in Expert Opinion on Biological Therapy (Just accepted, 2024)
-
Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-08-30 Astero Klampatsa
Published in Expert Opinion on Biological Therapy (Just accepted, 2024)
-
The current status of immunotherapy and future horizon in the treatment of metastatic and locally advanced gastroesophageal adenocarcinoma Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-08-28 Izuma Nakayama, Kohei Shitara
Immunochemotherapy with PD-1 blockade has been established as the current standard first-line therapy for patients with mGEA. Reviewing the history of clinical trials offers valuable insight into t...
-
The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-08-27 Giuseppe Lopalco, Andrea Cito, Vincenzo Venerito, Florenzo Iannone, Fabian Proft
Axial involvement in spondyloarthritis has significantly evolved from the original 1984 New York criteria for ankylosing spondylitis, leading to an improved understanding of axial spondyloarthritis...
-
T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-08-26 Marise R. Heerma van Voss, Remco J. Molenaar, Charlotte L.B.M. Korst, Imke H. Bartelink, Serena R. Baglio, Sandy Kruyswijk, Maaike de Ruijter, Sonja Zweegman, Maria T. Kuipers, Niels W.C.J. van de Donk
T-cell redirecting bispecific antibodies (BsAbs), targeting B-cell maturation antigen (BCMA) or G-protein – coupled receptor class C group 5 member D (GPRC5D), are efficacious new agents for the tr...
-
Perispinal etanercept stroke trial design: PESTO and beyond Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-08-23 Edward Tobinick, Danielle Ucci, Kirsten Bermudo, Samantha Asseraf
Perispinal etanercept (PSE) is an innovative treatment designed to improve stroke recovery by addressing chronic post-stroke neuroinflammation. Basic science evidence, randomized clinical trial (RC...
-
Current status and new avenues of stem cell-based preclinical and therapeutic approaches in amyotrophic lateral sclerosis Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-08-23 Letizia Mazzini, Fabiola De Marchi, Leonora Buzanska, Antonia Follenzi, Joel Clinton Glover, Maurizio Gelati, Ivan Lombardi, Margherita Maioli, Fatima Mesa-Herrera, Dinko Mitrečić, Cristina Olgasi, Augustas Pivoriūnas, Rosario Sanchez-Pernaute, Chiara Sgromo, Marzena Zychowicz, Angelo Vescovi, Daniela Ferrari
Cell therapy development represents a critical challenge in amyotrophic lateral sclerosis (ALS) research. Despite more than 20 years of basic and clinical research, no definitive safety and efficac...
-
IL-17 inhibitors in axial spondyloarthritis. An overview Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-08-17 Eric Toussirot, Renaud Felten
The therapeutic armamentarium for spondyloarthritis has expanded considerably in recent years, and there is growing evidence to support the increasing use of IL-17 inhibitors (IL-17i) in axial spon...
-
The FDA approval of delandistrogene moxeparvovec-rokl for duchenne muscular dystrophy: a critical examination of the evidence and regulatory process Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-08-17 Mehul Bhattacharyya, Larry E Miller, Anna L. Miller, Ruemon Bhattacharyya
Published in Expert Opinion on Biological Therapy (Just accepted, 2024)
-
How comparative studies can inform treatment decisions for Crohn’s disease Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-08-12 Giuseppe Privitera, Cristina Bezzio, Arianna Dal Buono, Roberto Gabbiadini, Laura Loy, Luca Brandaleone, Giacomo Marcozzi, Giulia Migliorisi, Alessandro Armuzzi
As new therapies for the treatment of Crohn’s disease (CD) are approved, there is an increasing need for evidence that clarifies their positioning and sequencing.Comparative effectiveness research ...
-
Clinical management and innovation in fracture nonunion Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-08-09 C. Siverino, W-J. Metsemakers, R. Sutter, E. Della Bella, M. Morgenstern, J. Barcik, M. Ernst, M. D’Este, A. Joeris, M. Chittò, P. Schwarzenberg, M. Stoddart, N. Vanvelk, G. Richards, E. Wehrle, F. Weisemann, S. Zeiter, C. Zalavras, P. Varga, T. F. Moriarty
With the introduction and continuous improvement in operative fracture fixation, even the most severe bone fractures can be treated with a high rate of successful healing. However, healing complica...
-
Correction Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-08-08
Published in Expert Opinion on Biological Therapy (Ahead of Print, 2024)
-
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19 Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-08-06 Arturo Casadevall, Scott McConnell, Daniele Focosi
Monoclonal antibody (mAb) therapies proved safe and effective in preventing progression of COVID-19 to hospitalization, but most were eventually defeated by continued viral evolution. mAb combinati...
-
Real-life data of etanercept efficacy and safety in juvenile idiopathic arthritis: a 24-month retrospective study at a single center Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-08-06 Ramazan Emre Yiğit, Kadir Ulu, Şengül Çağlayan, Betül Sözeri
The aim of this study was to assess the efficacy and safety of etanercept (ETA) use in juvenile idiopathic arthritis (JIA).The 24-month data of patients with JIA on etanercept in a single center we...
-
Correction Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-08-02
Published in Expert Opinion on Biological Therapy (Vol. 24, No. 8, 2024)
-
The chimera of reaching a universal consensus on platelet-rich plasma treatment for knee osteoarthritis: a review of recent consensus statements and expert opinion Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-08-02 Elizaveta Kon, Giuseppe Anzillotti, Pietro Conte, Luca Ruosi, Brian Cole, Jason Dragoo, Ken Zaslav, Rachel Frank, Laura De Girolamo, Bert Mandelbaum, Scott Rodeo, Maurilio Marcacci, Giuseppe Filardo, Berardo Di Matteo
Osteoarthritis (OA) is a prevalent cause of disability worldwide, affecting millions and posing significant socioeconomic burdens. Various conservative measures like hyaluronic acid (HA) and platel...
-
Intraparenchymal delivery of adeno-associated virus vectors for the gene therapy of neurological diseases Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-07-31 Shinichi Kumagai, Takeshi Nakajima, Shin-ichi Muramatsu
In gene therapy with adeno-associated virus (AAV) vectors for diseases of the central nervous system, the vectors can be administered into blood vessels, cerebrospinal fluid space, or the brain par...
-
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-07-29 Daniel R. Reed, Lawrence G. Lum
Since the approval of the bispecific antibody blinatumomab in 2017 for the treatment of acute lymphoblastic leukemia in relapse, the development of numerous bispecific antibody constructs has drama...
-
Infliximab biosimilar GP1111: a review of 5 years’ post-approval experience Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-07-27 Thomas W. J. Huizinga, Valeria Dipasquale, Markus Zabransky, Jens Heyn, Claudio Romano
Infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha, and GP1111 (Zessly®, Sandoz) is the most recently approved infliximab biosimilar in Europe. We reviewed the approva...
-
The role of bDMARDs in the prevention and treatment of inflammatory-related comorbidities in Psoriatic Arthritis Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-07-26 Francesco Caso, Mauro Fatica, Mario Ferraioli, Matteo Megna, Luca Potestio, Angelo Ruggiero, Nello Tommasino, Francesco Maione, Raffaele Scarpa, Maria Sole Chimenti, Luisa Costa
Psoriatic arthritis (PsA) is an immune-inflammatory disease that affects both joints and entheses, and with diverse extra-articular manifestations (psoriasis, inflammatory bowel disease (IBD), and ...
-
Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-07-25 Aliki I. Venetsanopoulou, Paraskevi V. Voulgari, Alexandros A. Drosos
Rheumatoid arthritis (RA) is a chronic autoimmune disease that significantly impacts patients’ quality of life. While treatment options have expanded over the years, including the introduction of t...
-
The nail in psoriatic arthritis: new insights into prognosis and treatment Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-07-25 Rubén Queiro, Sara Alonso, Jose A. Pinto-Tasende
Published in Expert Opinion on Biological Therapy (Vol. 24, No. 8, 2024)
-
The potential for medical therapies to address fistulizing Crohn’s disease: a state-of-the-art review Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-07-24 Mohammad Shehab, Davide De Marco, Peter L. Lakatos, Talat Bessissow
Crohn’s disease (CD) is a chronic, relapsing immune mediated disease, which is one of the two major types of inflammatory bowel disease (IBD). Fistulizing CD poses a significant clinical challenge ...
-
Long-acting delivery and therapies for neovascular age-related macular degeneration Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-07-22 Lucas W. Rowe, Thomas A. Ciulla
Neovascular age-related macular degeneration (nAMD) represents a leading cause of severe visual impairment in individuals over 50 years of age in developed nations. Intravitreal anti-vascular endot...
-
Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-07-18 Gary R. Lichtenstein, Arif Soonasra, Mark Latymer, Sheena Singh, Brian G. Feagan
Infliximab (IFX) biosimilars are available to treat inflammatory bowel disease (IBD), offering cost reductions versus originator IFX in some jurisdictions. However, concerns remain regarding the ef...
-
Revisions to the requirement of the Japanese clinical study data for biosimilar developments in Japan Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-07-09 Ryosuke Kuribayashi, Kanoko Goto, Aya Hariu, Yasuhiro Kishioka
The ‘Questions and Answers (Q&A)’ document regarding Japanese biosimilar guideline elucidated that Japanese participant enrollment in at least one comparative clinical study was required for the ma...
-
Industry perspective on regulatory authority (RA) quality reviews of biosimilar applications – an evaluation of RA guidance and expectations for chemical, manufacturing, and controls information through in-depth query analysis Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-07-04 Heather Rae Hufnagel, Scott D Tennyson
Evaluate the type and quantity of quality information (i.e. Chemistry, Manufacturing, and Control) requested by the US FDA and EMA in queries pertaining to biosimilar applications.Numbers/types of ...
-
How close are we to a success stratification tool for improving biological therapy in ulcerative colitis? Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-06-26 Panu Wetwittayakhlang, Gynter Kotrri, Talat Bessissow, Peter L. Lakatos
Biological therapies have become the standard treatment for ulcerative colitis (UC). However, clinical remission rates post-induction therapy remain modest at 40–50%, with many initial responders l...
-
Comparative analysis of GMO regulatory requirements for AAV vectors in the EU and Japan focusing on the shedding data and containment measures Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-06-28 Hirokuni Mizoguchi, Tobias Fleischmann, Masato Komuro, Takahiro Hirai, Akiko Ikeda, Kojiro Saito, Tomohiro Watahiki, Gentaro Tajima
Recombinant viral-based gene therapy products, such as those incorporating adeno-associated viruses (AAVs), fall under the category of genetically modified organisms (GMOs). The European Union (EU)...
-
Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-06-28 Rahul Kapur, Shivani Mittra, Geetanjali Tonpe, Adithi P, Praveen Raj, Uwe Gudat, Sandeep N. Athalye
We evaluated a potential move from one rapid-acting insulin analog to another, or their biosimilars, to aid better and faster decisions for diabetes management.A systematic literature review was pe...
-
Small molecule-regulated switches to provide functional control of CAR T cells within the patient Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-06-29 Charlotte U. Zajc, Elise Sylvander, Manfred Lehner, Michael W. Traxlmayr
CAR T cells have generated great excitement due to their remarkable clinical response rates in selected hematologic malignancies. However, these engineered immune cells are living drugs which are h...
-
Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-06-29 Virginia E. Fontenot, Alex Francoeur, Krishnansu S. Tewari
Published in Expert Opinion on Biological Therapy (Vol. 24, No. 8, 2024)
-
Gene therapy for Leber hereditary optic neuropathy Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-06-28 Marco Battista, Valerio Carelli, Leonardo Bottazzi, Francesco Bandello, Maria Lucia Cascavilla, Piero Barboni
Leber hereditary optic neuropathy (LHON) is among the most frequent inherited mitochondrial disease, causing a severe visual impairment, mostly in young-adult males. The causative mtDNA variants (t...
-
Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-06-25 Luca Mastorino, Irene Richiardi, Federica Gelato, Giovanni Cavaliere, Pietro Quaglino, Michela Ortoncelli, Simone Ribero
There are currently limited data on dupilumab drug survival (DS), especially on factors possibly associated with drug discontinuation.The primary endpoint of this study is to evaluate the parameter...
-
Treatment options for advanced hepatocellular carcinoma: the potential of biologics Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-06-24 Federico Rossari, Silvia Foti, Silvia Camera, Mara Persano, Andrea Casadei-Gardini, Margherita Rimini
Advanced hepatocellular carcinoma (HCC) represents a significant global health burden, whose treatment has been recently revolutionized by the advent of biologic treatments. Despite that, innovativ...
-
Targeting gut and intratumoral microbiota: a novel strategy to improve therapy resistance in cancer with a focus on urologic tumors Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-06-24 Bingquan Wu, Chao Quan, Yunbo He, Juliet Matsika, Jinliang Huang, Bolong Liu, Jinbo Chen
Growing attention has been drawn to urologic tumors due to their rising incidence and suboptimal clinical treatment outcomes. Cancer therapy resistance poses a significant challenge in clinical onc...
-
Checkpoint inhibition for early-stage hormone receptor-positive breast cancer Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-06-24 Ilana Schlam, Chiara Corti, Sarah Sammons, Elizabeth A. Mittendorf, Sara M. Tolaney
Most patients with breast cancer have early-stage hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative disease. Even though the prognosis for most of these patie...
-
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-06-21 Kyung-Sang Yu, Hyunwook Ryu, Dongseong Shin, MinKyu Park, JunGi Hwang, Seol Ju Moon, Min-Gul Kim, Edward Keystone, Josef S Smolen, SungHyun Kim, YunJu Bae, DaBee Jeon, JiYoung Jang, GoEun Yang, JiHun Bae, JaeYong Lee, Gerd R Burmester
This study compared the pharmacokinetics (PK), immunogenicity, and safety of candidate tocilizumab biosimilar, CT-P47, administered via auto-injector (CT-P47 AI) or pre-filled syringe (CT-P47 PFS),...
-
Antibody-based therapeutics for chronic rhinosinusitis with nasal polyps Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-06-20 Shama Shishodia, Nora Haloob, Claire Hopkins
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a prevalent inflammatory condition with heterogenous underlying endotypes, the most common being type 2 mediated inflammation. Several biologics...
-
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma? Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-06-19 Matteo Rosellini, Andrea Marchetti, Elisa Tassinari, Veronica Mollica, Francesco Massari, Matteo Santoni
Published in Expert Opinion on Biological Therapy (Vol. 24, No. 6, 2024)
-
Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-06-19 Eden David, Kelly Hawkins, Neda Shokrian, Ester Del Duca, Emma Guttman-Yassky
The understanding of atopic dermatitis (AD) pathogenesis has rapidly expanded in recent years, catalyzing the development of new targeted monoclonal antibody treatments for AD.This review aims to s...
-
Management of proctitis in ulcerative colitis and the place of biological therapies Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-06-17 Diletta De Deo, Arianna Dal Buono, Roberto Gabbiadini, Paola Spaggiari, Anita Busacca, Benedetta Masoni, Silvia Ferretti, Cristina Bezzio, Alessandro Armuzzi
Approximately 20–30% of the patients with ulcerative colitis (UC) may present with isolated proctitis. Ulcerative proctitis (UP) is a challenging condition to manage due to its significant burden i...
-
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-06-13 Zine-Eddine Khene, Yair Lotan
BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) represent a significant therapeutic challenge in the treatment of bladder cancer. Nadofaragene firadenovec, represents a breakthrough in ...
-
Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-06-11 Nozomu Ogura, Shun Yamamoto, Ken Kato
The prognosis of advanced esophageal squamous cell carcinoma (ESCC) is poor. Although cytotoxic drugs have been widely used in advanced ESCC, several antibody agents have recently been reported to ...
-
Overview of biosimilar medicines in Spain: market dynamics, policies, evidence-based insights and avenues for a sustainable market Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-06-06 Isabel Río-Álvarez, Encarnación Cruz-Martos
After 17 years on the market, biosimilar medicines have contributed significantly to the sustainability of healthcare in Spain, providing cost-effective treatment options and savings of more than €...
-
Understanding patient variability to biologic treatments in inflammatory bowel disease Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-05-26 Ahmad Z. Al Meslamani
Published in Expert Opinion on Biological Therapy (Vol. 24, No. 5, 2024)
-
Next-generation CD40 agonists for cancer immunotherapy Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-05-23 Hampus Andersson, Barnabas Nyesiga, Tova Hermodsson, Karin Enell Smith, Karin Hägerbrand, Malin Lindstedt, Peter Ellmark
There is a need for new therapies that can enhance response rates and broaden the number of cancer indications where immunotherapies provide clinical benefit. CD40 targeting therapies provide an op...
-
Could siRNA therapeutics change the way we treat dyslipidemia? Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-05-22 Peter E. Penson, Alice P. McCloskey
Published in Expert Opinion on Biological Therapy (Vol. 24, No. 5, 2024)
-
Non-TNF biologics and their biosimilars in rheumatoid arthritis Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-05-22 Tsz Ching Mok, Chi Chiu Mok
Rheumatoid arthritis (RA) is a chronic inflammatory rheumatic disease that affects both the articular and extra-articular structures, leading to significant joint damage, disability and excess mort...
-
Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database network Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-05-21 Andrea Spini, Giorgia Pellegrini, Ylenia Ingrasciotta, Luca L’Abbate, Chiara Bellitto, Massimo Carollo, Olivia Leoni, Martina Zanforlini, Domenica Ancona, Paolo Stella, Anna Cavazzana, Angela Scapin, Sara Lopes, Valeria Belleudi, Stefano Ledda, Paolo Carta, Paola Rossi, Lucian Ejlli, Ester Sapigni, Aurora Puccini, Stefania Spila Alegiani, Marco Massari, Claudio Guarneri, Paolo Gisondi, Gianluca Trifirò
Switch patterns among different biologics and from originators to biosimilars (and vice versa) can be complex in patients with psoriasis (PsO) and psoriatic arthritis (PsA).The aim of this study wa...
-
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature Expert Opin. Biol. Ther. (IF 3.6) Pub Date : 2024-05-19 Emiliano Barbieri, Enrica Antonia Martino, Elena Rivolti, Micol Quaresima, Ernesto Vigna, Antonino Neri, Fortunato Morabito, Massimo Gentile
Gain/amplification of 1q (+1q) represents one of the most prevalent cytogenetic abnormalities (CAs) observed in multiple myeloma (MM). Historical studies predating the advent of anti-CD38 monoclona...